Inovio planning for ex-us global phase 3 trial for ino-4800

Plymouth meeting, pa., april 23, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that it is planning for a predominantly ex-u.s. phase 3 trial for its covid-19 vaccine candidate, ino-4800.

INO Ratings Summary

INO Quant Ranking